Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Restructuring Costs (2023)

Rein Therapeutics (RNTX) has disclosed Restructuring Costs for 1 consecutive years, with -$12000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Restructuring Costs changed N/A to -$12000.0 in Q4 2023 year-over-year; TTM through Sep 2024 was -$12000.0, a N/A change, with the full-year FY2023 number at $928000.0, changed N/A from a year prior.
  • Restructuring Costs was -$12000.0 for Q4 2023 at Rein Therapeutics, down from $6000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $1.0 million in Q1 2023 to a low of -$88000.0 in Q2 2023.